

GOG PARTNERS CONNECTION

A Quarterly Newsletter From GOG Partners, A GOG Foundation Program

THE HERZOG REPORT

We Need YOU: Continuing the Conversation from the NRG 2025 Summer Meeting

At the NRG Summer Meeting in July, we introduced the theme “We Want YOU”—a rallying call to recognize and empower the extraordinary individuals and institutions that make up our GOG Foundation (GOG-F) network.

That message wasn’t just symbolic; it was a declaration of intent. Since then, we’ve been listening closely, gathering insights, and reflecting on how we can better support you in the work that truly transforms lives and the standard of care in gynecologic oncology. My message to you today is a continuation of that commitment—a deeper dive into what we’ve learned from your feedback, what challenges you face, and how we plan to turn this collective momentum into meaningful action.

I want to first take a moment to extend a sincere thank you to everyone who took the time to complete our post-July meeting survey. Your feedback offered a clear and candid view into the operational challenges many sites face—from budget and contract negotiations to staffing shortages, regulatory delays, and patient recruitment hurdles. These insights have been invaluable in shaping our strategy. While the barriers are real, so are the opportunities. Your suggestions—ranging from broader eligibility criteria and streamlined activation workflows to improved communication tools and dedicated site liaisons—point to practical, achievable solutions. By addressing these pain points collaboratively, we can accelerate trial start-up, enhance site sustainability, and ultimately expand access to innovative care. Together, we have the potential to transform not only how trials are activated, but how patients experience research-driven treatment.

The survey results convey a clear message: sites are deeply committed to clinical research, but greater support, flexibility, and collaborative partnerships are needed to thrive. The GOG-F is committed to addressing these challenges head-on to help every investigator and site succeed. Our continued efforts and collaboration will be essential as together we strive toward a more inclusive, efficient, and impactful research ecosystem. Over the next few years we anticipate activating approximately 30 new studies, significantly expanding patient access to novel therapeutic options. Therefore, our strategy is focused and intentional:

- Re-engaging and revitalizing sites that have paused
- Maximizing growth opportunities at all sites
- Helping each site to achieve its full potential
- Cultivating accrual culture in new and emerging locations
- Recognizing and celebrating high performance through authorship

These priorities are more than operational goals—they reflect our shared mission to transform patient-centered gynecologic cancer care through innovation, research, and education. Guided by our core values of service, integrity, resiliency, collaborative excellence, and transformational impact, we are building a future where every site is empowered, every patient has access to cutting-edge care, and every trial moves us closer to meaningful change.

As the Harvard Business Review reminds us: “Every great culture needs a mission, a vision, and values...But these are never meant to be static.”

We embrace this moment as an invitation to evolve together, as we are not just expanding our research capabilities, but strategically shaping the future of gynecologic oncology, and transforming the standard of care.

With Warmest Regards,
Tom



Thomas Herzog, MD
President, The GOG Foundation, Inc.
University of Cincinnati

If you have not taken the survey, I invite you to please share your feedback



The more feedback that we receive, the more likely that we will be able to develop plans that best address the needs of your site.



Our Mission is clear:

To transform patient-centered gynecologic cancer care through innovation, research, and education.



Our Vision is bold:

To be the premier collaborative network for transformative research in gynecologic malignancies.



Education in Gynecologic Oncology Clinical Trials

In today's dynamic gynecologic oncology landscape, education is essential to transforming innovation into impact. The GOG-F's vision to be the premier collaborative network for transformative research in gynecologic oncology and ultimately to transform the standard of care™ not only through clinical trials, but through the education we provide. Education bridges discovery and insight — empowering patients, providers, and researchers to meaningfully understand and interpret how to advance care. With novel therapies and trial designs emerging rapidly, access to information is easier than ever. But access alone isn't enough. In a sea of data, context is critical. GOG's complimentary education helps physicians, patients, advanced practice providers, pharmacists, nurses, and caregivers gain insightful access to new opportunities and understand the options available. Without robust educational frameworks, even the most promising innovations risk being overlooked or misunderstood.



Jenna Cummins-Kien, CMP
Executive Director, Business Development
The GOG Foundation, Inc.

To support a diverse and global community of clinicians, researchers, and patients, the GOG-F provides the majority of our education as a complimentary resource.

Educational Offerings Include:

- [GOG Highlight Reel](#) – Key updates and breakthroughs in gynecologic oncology.
- [Accrual Culture Initiative](#) – Targeted education to enhance trial participation.
- [GOG Podcast Channel](#) – Flexible, on-the-go learning for busy professionals through your preferred podcast platforms, More detail coming soon!
- [Industry Supported Symposia](#) – In-depth exploration of emerging therapies and trial data.
- Important Educational Partnership – Expanding global access to best practices and cutting-edge research through international partnerships

These materials are available on [GOG.org](#) and the [GOG Foundation YouTube channel](#), ensuring broad reach and ease of access. The GOG's YouTube channel has seen a significant increase in engagement, with top-performing videos reaching thousands of views — a testament to the demand for high-quality, accessible education.

The GOG-F is proud to be an ACCME-accredited organization through the Accreditation Council for Continuing Medical Education (ACCME). This designation reflects our commitment to delivering educational content that meets the highest standards of quality, independence, and relevance. All GOG educational offerings are developed without commercial bias or influence. Each program undergoes a rigorous review process led by a dedicated committee of ten experts chaired by Dr. Angeles Alvarez Secord. This team ensures that every resource is:

- Evidence-based
- Clinically relevant
- Receptive to our learner's needs and educational gaps
- Aligned with ACCME standards
- Responsive to real-world challenges

Through comprehensive gap analyses and needs assessments, we tailor content to address the evolving needs of gynecologic oncology professionals. Whether it's a podcast, symposium, or video series, our goal is to provide accessible, unbiased education that supports informed decision-making and helps transform the standard of care. Evaluation feedback empowers informed decision-making, supports trial enrollment, and ultimately contributes to better patient outcomes. Complimentary, high-quality education remains a powerful tool to bridge access or socioeconomic gaps. In this field, our goal is to provide education to all that supports the journey from research to improved outcomes in gynecologic oncology.

As we continue to navigate the complexities of clinical trials and cancer research, education will remain at the forefront of our mission. By giving access to knowledge, we're not just informing — we're transforming. Together, we can build a future where every patient has the opportunity to benefit from the latest advancements in gynecologic oncology.

On behalf of the GOG-F, I welcome you to explore our educational resources, share them with your networks, and help us create a culture of informed care. If there is a topic or resource that interests you that we have yet to provide content for, please do not hesitate to reach out to us with any educational request. Through education, we create opportunities to transform the standard of care — elevating knowledge, expanding access, and ultimately striving to improve lives.



IGCS 2025 ANNUAL GLOBAL MEETING


IGCS 2025
 Annual Global Meeting
CAPE TOWN
 November 5 - 7

You are invited to the 2025 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), which will be held at **Century City Conference Centre in Cape Town, South Africa from November 5-7, 2025.**

The IGCS Meeting is a platform for exchanging insights, sharing research findings, and discussing best practices. It's an opportunity to build professional networks, foster collaborations, and learn from some of the brightest minds in the field. Don't miss the chance to be part of this global community striving to make a difference in the lives of women affected by gynecologic cancers!

Industry Supported Symposia

[Register for IGCS](#)

The GOG-F and IGCS are pleased to continue a strategic partnership whereby the GOG-F collaborates with the IGCS to manage the Industry Supported Symposia (ISS) at the 2025 IGCS Annual Global Meeting in Cape Town, South Africa, November 5 – 7, 2025.

Our collaboration allows us to bring the most relevant topics for symposia each year and the optimal delivery method that complements the abstracts and education delivered by the IGCS Program Committee.

To participate in these In-Person, non-CME Symposia, attendees must be registered to attend the IGCS 2025 Annual Global Meeting.

[Click here](#) to learn more about these educational programs. *These sessions are not included in main conference CME/CPD credit.*

Wednesday, November 5, 2025

The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers

Moderator: Dr. Ramez Eskander | Faculty: Dr. Robert Coleman, Dr. Bhavana Pothuri

This educational activity is supported by an independent medical education grant from GSK

Innovative Horizons: Advancing Platinum-Resistant Ovarian Cancer (PROC) Treatment with Antibody-Drug Conjugates (ADCs)

Moderator: Prof. Kathleen Moore | Faculty: Prof. Isabelle Ray-Coquard, Prof. David O'Malley

This industry satellite symposium is organised and funded by Daiichi Sankyo and MSD

Thursday, November 6, 2025

Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer

Moderator: Dr. Christian Marth | Faculty: Dr. Ramez Eskander, Dr. Leslie Randall, Dr. Alexander Olawaiye

Eisai has sponsored this initiative with IGCS and had no input into or influence over the content

A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies

Moderator: Dr. Brian Slomovitz | Faculty: Dr. Saketh Guntupalli, Dr. Susana Banerjee

This educational activity is supported by an independent medical education grant from Verastem

Global Perspective in Advanced, Recurrent Cervical Cancer: Resources, Opportunities and Access to Care

Moderator: Dr. Leslie Randall | Faculty: Dr. Kosei Hasegawa, Dr. Ritu Salani

This educational activity is supported by an independent medical education grant from Genmab

Friday, November 7, 2025

Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial: Equitable, Individualized and Accessible Care

Moderator: Dr. Bradley Monk | Faculty: Dr. Scott Jordan, Dr. R. Wendel Naumann, Dr. Shannon Westin

This educational activity is supported by an independent medical education grant from AstraZeneca

Beyond the Image: New Opportunities in Gynecologic Cancer Testing

Moderator: Dr. Thomas Herzog | Faculty: Dr. Stephanie Lheureux, Dr. Kathleen Moore

This educational activity is supported by an independent medical education grant from Natera

From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer

Moderator: Dr. Debra Richardson | Faculty: Dr. Nicoletta Colombo, Dr. Domenica Lorusso, Dr. David O'Malley

This educational activity is supported by an independent medical education grant from Corcept Therapeutics, Inc.

Unlocking Endometrial Cancer Care: Applying Changing Standards into Clinical Practice

Moderator: Dr. Keo Tabane | Faculty: Dr. Ramez Eskander, Dr. Christian Marth

Symposium sponsored by MSD

This program is not intended for healthcare professionals who practice in, are licensed to practice in, or reside in the U.S., its territories, or Puerto Rico.



ENDURING EDUCATION

Medscape and the GOG-F welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the **Pairing Data With Experience to Optimize Care in Advanced Ovarian Cancer**, an Industry Supported Symposium that was presented at the NRG 2025 Summer Meeting on Friday, July 25, 2025.



UPCOMING INDUSTRY MEETINGS

ESMO 2025 CONGRESS

Save the date for ESMO 2025, taking place in **Berlin, Germany 17-21 October 2025**.

The ESMO Congress is a highly influential global oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

ESMO 2025 will be a place where groundbreaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care. You will be able to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals that are driving advancements in diagnosis, treatment and survivorship.

[Click here](#) for more information on the meeting.



GCIG Autumn 2025 Meeting

The GCIG Autumn 2025 meeting will be held **October 15 and 16, 2025** (prior to ESMO 17 Oct 2025-21 Oct 2025) in **Berlin, Germany at Kaiserin Friedrich-Stiftung** (Robert-Koch-Platz 7 in 10115 Berlin).



[Click here](#) for more information on the GCIG Autumn Meeting.

NRG Winter 2026 Meeting

The NRG Winter 2026 Semiannual Meeting will be held in person at the **Hilton San Francisco Union Square** in **San Francisco, California, from January 22 - 24, 2026**.

NRG Oncology will offer a full program that includes scientific sessions, engaged educational session for early-career investigators, and opportunities for networking events. We are excited to offer an expanded Winter Symposium. Learn more about the full program on the Agenda & Session Information page (coming soon). Select sessions will be held virtually ahead of the in-person meeting.

[Click here](#) for more information on the NRG 2026 Winter Meeting!



GOG Highlight Reel - January 2026



The GOG-F and GOG-P welcome gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend The GOG Highlight Reel - January 2026 education program presented in person in **San Francisco, California on Friday, January 23, 2026 from 6:30 - 9:00 pm PT**.

The January 2026 Highlight Reel will be offered in person only. Registration is anticipated to open mid-November.



CLINICAL TRIALS

The GOG-P Program is currently recruiting for 28 clinical trials

- 13 Ovary
- 4 Cervix
- 11 Endometrium

To learn more about GOG-P Clinical Trials, please contact Katie Campbell at kcampbell@gog.org.



Executive Director, Clinical Trials Operations
The GOG Foundation, Inc.

Clinical Trials Spotlight

GOG-3043: A Randomized Controlled Trial of Robotic versus Open Surgery for Early Stage for Cervical Cancer

GOG-3116: A Prospective Low-Interventional Phase 4 Single Arm Study of ocular assessments in patients treated with TIVDAK® in Recurrent or Metastatic Cervical Cancer

GOG-3098/ ENGOT-EN24 (DESTINY-01): DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)

GOG-3119/ ENGOT-en29 (TroFuse-033): A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer

GOG-3122 (DESTINY-Endometrial 02): A Phase 3, Multicenter, Randomized, Open label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

GOG-3110 (Bluestar-Endometrial01): A Phase III, randomized, double-blind trial assessing the efficacy and safety of BNT323 plus dostarlimab versus placebo plus dostarlimab in participants with recurrent or primary advanced HER2-expressing endometrial cancer

GOG-3111: An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel and an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

GOG-3066 (DENALI): A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of Azenosertib (ZN-c3) in Subjects with Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

GOG-3096 / ENGOT-ov77 (REJOICE-Ovarian01): A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

GOG-3107 (RAINFOL-OV2): A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer

GOG-3076 (OnPrime): A Randomized Phase 3 Study Assessing the Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC)

GOG-3121 (ULTIMUS-1): Randomized Phase 2/3 Trial of NP-G2-044 Combined with PLD for Treatment of Platinum-Resistant Ovarian Cancer

Search
Active Clinical Trials



IN THE NEWS

ESMO 30 YEARS PUBLICATION

FINDINGS FROM THE NRG ONCOLOGY GOG-263 | KGOG1008 STUDY

Weekly Cisplatin-Based
Chemoradiotherapy Improves RFS and
OS, Although Not Statistically Significant,
for Patients with Cervical Cancer and
Intermediate Pathologic Risk Factors



“

GOG-263 built upon the legacy of prior GOG cervical cancer investigators further evaluating the role of post-operative radiation, with or without chemotherapy, following radical hysterectomy.

Perhaps most importantly was the clear international collaboration from the KGOG and the multitude of investigators to address this important clinical question.

As demonstrated, outcomes favored the addition of chemotherapy to post-operative radiation these were not statistically significant, although this observation may be tempered by the lower than planned overall study enrollment.

”



Charles Leath, MD
University of Alabama at Birmingham
O'Neal Comprehensive
Cancer Center in Birmingham



PUBLICATION

The GOG Foundation and
EVA/LACOG Partnership:
A Collaborative Strategic Alliance
for Clinical Trial Execution



“

This publication in IJGC formalizes the exceptional partnership between the GOG and LACOG-EVA, setting forth the terms of this mutual cooperation with the goal of promoting research and helping patients with gynecologic cancer achieve a better future.

In addition, this partnership fosters research in Latin America, strengthening the region's role in the global innovation landscape. On behalf of the LACOG-EVA our special thanks to Professor Thomas J. Herzog and to all GOG leaders who made this collaboration possible.

”



Fernando Maluf, MD, PhD
Beneficencia Portuguesa

**XPORT-EC-042
GOG-3083 / ENGOT-EN20**

EXPERT REVIEW OF ANTICANCER THERAPY PUBLICATION

An evaluation of selinexor as a
maintenance therapy for patients
with p53 wild-type, advanced, or
recurrent endometrial carcinoma

“

This comprehensive review in Expert Review of Anticancer Therapy provides critical scientific rationale for targeting TP53 wild-type endometrial cancer with selinexor, highlighting the unique mechanism of XPO1 inhibition and promising efficacy signals from earlier studies.

The insights presented in this manuscript directly support our ongoing ENGOT-EN20/ GOG-3083/ XPORT-EC-042 trial in collaboration with The GOG Foundation, where we are rigorously evaluating selinexor maintenance therapy to potentially transform outcomes for this underserved patient population with limited treatment options.

”



Robert Coleman, MD
Texas Oncology



IN THE NEWS



PRESS RELEASE

REJOICE-Ovarian01 GOG-3096 / ENGOT-ov77

Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab



“

GOG-3096 is one of the most exciting trials recruiting PROC patients right now.

R-DXd has an ORR of about 50% in unselected patients.

Let's keep the momentum going to complete the phase 2 extension and open the phase 3 randomized trial.

”




DEBRA RICHARDSON, MD
 UNIVERSITY OF OKLAHOMA, STEPHENSON CANCER CENTER
 OKLAHOMA CITY, OKLAHOMA



PRESS RELEASE

Genmab Receives FDA Breakthrough Therapy Designation for Rinatubart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)



The FDA Breakthrough Therapy Designation for Rina-S® for the treatment of patients with advanced endometrial cancer is a pivotal step, showing the potential to transform targeted therapy into clinical meaningful benefit and suggesting the growing role of ADCs in the management of gynecologic cancer.

Noelle Cloven, MD
 Texas Oncology,
 Fort Worth Cancer Center

LET'S CONNECT



@gogfoundation.bsky.social



@GOGFOUNDATION



@gog_foundation



The GOG Foundation, Inc.



@gogfoundation3870



@GOG



GOG 2025 INDUSTRY SPONSORS

The GOG-F and GOG-P would like to thank our Year-Round Sponsors for their support of our mission to transform the standard of care in gynecologic oncology.

EXECUTIVE PLATINUM SPONSORS



PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



LET'S END THE SILENCE AROUND
ENDOMETRIAL CANCER

Access resources for your patients at SpotHerForEC.com

US5619